BioNews TexasNIH Study For Secondary-Progressive MS Underway On Experimental Drug …BioNews TexasIn this study, Rituximab be delivered intravenously and directly into the cerebrospinal fluid by lumbar puncture of about 80 people with secondary-progres…
|
A Pill ‘Melts Away’ Common Form Of Leukemia
RedOrbit They found that those who received the combination of idelalsib and rituximab went longer without their disease worsening than those who received only rituximab, which has been the standard of care. Six months into the study, cancers in 93 percent of … |
|
Halozyme Therapeutics recommended for European Commission approval
San Diego Source (subscription) The treatment is Roche’s subcutaneous formulation of MabThera (rituximab) using Halozyme’s recombinant human hyaluronidase (rHuPH20). “This subcutaneous formulation of MabThera, pending approval in the EU, provides a new route of administration … Halozyme Announces Positive Opinion From CHMP For European Approval Of …PR Newswire (press release) |
A pill may replace chemo in treating leukemiaManoramaonlineA team of researchers from 19 medical centres in five countries have found that use of a combination of two targeted drugs – idelalsib and rituximab – can make the use of debilitating chemother…
HIV-1 Envelope Immunogens Elicit Antibodies Associated with Vaccine ProtectionInfection Control TodaySeattle BioMed researchers have identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine. The …
|
Researchers Identify Two HIV-1 Envelope Immunogens Capable of Eliciting …
Newswise (press release) Newswise — Seattle, WA., January 24, 2013 — Seattle BioMed researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine. The study was published online in PLOS One. The HIV-1 … HIV-1 Envelope Immunogens Elicit Antibodies Associated with Vaccine ProtectionInfection Control Today |
|
Pharma In Brief – Federal Court Considers Functional Antibody Claims Valid And …
Mondaq News Alerts (registration) Justice Hughes dismissed Janssen’s allegation that claims 143 and 222 were overbroad, even though these claims were found to cover antibodies and methods that were not exemplified in the ‘281 Patent. STELARA® was held to infringe claims 143 and 222 … |
Financial Express |
A pill may replace chemotherapy in treating leukemia
Daijiworld.com A team of researchers from 19 medical centres in five countries have found that use of a combination of two targeted drugs – idelalsib and rituximab – can make the use of debilitating chemotherapy redundant in the treatment of CLL, a cancer of the … Pill ‘melts away’ common form of leukaemiaBusiness Standard New pill can ‘melt away’ leukemia without chemotherapyTruthDive |
|
NICE set to extend MabThera recommendation
PMLiVE Final draft guidance from the National Institute for Health and Care Excellence (NICE) recommends MabThera (rituximab) be available for use on the NHS to treat severe forms of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). UK’s NICE gives green light to Roche’s MabThera for GPA and MPAThe Pharma Letter |
Drug Discovery & Development |
Use of twice-daily pill could turn deadly blood cancer into highly treatable …
News-Medical.net They found that those who received the combination of idelalsib and rituximab went longer without their disease worsening than those who received only rituximab, which has been the standard of care. Six months into the study, cancers in 93 percent of … New pill can ‘melt away’ leukemia without chemotherapyZee News A pill may replace chemotherapy in treating leukemiaBusiness Standard |